Live Breaking News & Updates on Heart Failure Therapeutics|Page 2

Stay updated with breaking news from Heart failure therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Brian Mullen , Chris Giordano , Baylor Scott White , Daniel Burkhoff , Sanjiv Shah , Javed Butler , John Fraunces , Northwestern University , Research For The Bluhm Cardiovascular Institute , Company Secured Global Commercial Rights To Levosimendan , Lifesci Advisors , Orion Corporation , Tenax Therapeutics Inc , Cardiovascular Research Foundation Technology , Nasdaq Stock Market , Columbia University , Trademark Office , Clinical Development Updates , Therapeutics Provides Business , Full Year , Patient Enrolled , Pulmonary Hypertension , Heart Failure , Preserved Ejection Fraction , Property Covering ,

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results - Tenax Therapeutics (NASDAQ:TENX)

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S. ....

United States , John Fraunces , Baylor Scott White , Daniel Burkhoff , Chris Giordano , Sanjiv Shah , Javed Butler , Brian Mullen , Cardiovascular Research Foundation Technology , Trademark Office , Lifesci Advisors , Orion Corporation , Company Secured Global Commercial Rights To Levosimendan , Northwestern University , Tenax Therapeutics Inc , Columbia University , Research For The Bluhm Cardiovascular Institute , Nasdaq Stock Market , Patient Enrolled , Pulmonary Hypertension , Heart Failure , Preserved Ejection Fraction , Property Covering , Company Secured Global Commercial Rights , Scientific Rationale , First Treatment ,

BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results -March 27, 2024 at 01:30 pm EDT

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

March 27, 2024

BioCardia®, Inc. [Nasdaq: BCDA], a developer of. ....

United States , Finkelstein Schoenfeld , Peter Altman , Device Agency , Medicaid Services , Exchange Commission On , Biocardia Inc , Maryland Stem Cell Research Fund , Exchange Commission , Biocardia Reports Fourth Quarter , Full Year , Financial Results , Morph Access Innovations , Autologous Cell Therapy , Therapy Heart Failure , Heart Failure Therapy , Major Adverse Coronary , Cerebrovascular Events , Failure Trial , Cell Therapy , Chronic Myocardial Ischemia , Therapy Chronic Myocardial Ischemia Trial , Mesenchymal Stem Cells , Heart Failure Therapeutics , Therapy Heart Failure Trial , Heart Failure ,

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , David Mcclung , Miranda Peto , Finkelstein Schoenfeld , Peter Altman , Company Annual Report On Form , Exchange Commission , Exchange Commission On , Biocardia Inc , Maryland Stem Cell Research Fund , Device Agency , Biocardia Inc Selected Balance Sheet Data , Medicaid Services , Biocardia Inc Consolidated Statements Of Operations , Morph Access Innovations , Autologous Cell Therapy , Therapy Heart Failure , Heart Failure Therapy , Major Adverse Coronary , Cerebrovascular Events , Failure Trial , Cell Therapy , Chronic Myocardial Ischemia , Therapy Chronic Myocardial Ischemia Trial , Mesenchymal Stem Cells , Heart Failure Therapeutics ,

Biocardia Reports Fourth Quarter And Full Year 2023 Business Highlights And Financial Results

Biocardia Reports Fourth Quarter And Full Year 2023 Business Highlights And Financial Results
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United States , Peter Altman , Miranda Peto , Finkelstein Schoenfeld , David Mcclung , Device Agency , Exchange Commission On , Medicaid Services , Exchange Commission , Biocardia Inc , Maryland Stem Cell Research Fund , Morph Access Innovations , Autologous Cell Therapy , Therapy Heart Failure , Heart Failure Therapy , Major Adverse Coronary , Cerebrovascular Events , Failure Trial , Cell Therapy , Chronic Myocardial Ischemia , Therapy Chronic Myocardial Ischemia Trial , Mesenchymal Stem Cells , Heart Failure Therapeutics , Therapy Heart Failure Trial , Heart Failure , Reduced Ejection Fraction ,